Association of common polymorphisms in p 53 and MDM 2 with platinum-related grade III / IV toxicities in Chinese advanced lung adenocarcinoma patients

Dong Guo,Yanbing Zhou,Zhen Guo,Jianfeng Gong,Yao Wei,Weiming Zhu

2016-01-01

Abstract:Lung adenocarcinoma (LAC) is a predominant form of lung cancer worldwide with a high mortality. The treatment-related toxicity is an important side effect for the patients with advanced disease after combined chemotherapy. MDM2-p53 pathway have lead role in regulation of platinum-induced DNA damage responses, and the functional polymorphisms could affect the capacity to DNA damage responses and apoptosis of normal tissue cells. Herein we investigated two common polymorphisms of p53 and MDM2 genes, rs1042522 and rs2279744, and their associations with the occurrence of grade III/IV toxicities by logistic regression models in 292 stage III and IV lung adenocarcinoma patients following the first-line with platinum-based chemotherapy. Adjusting covariates were age, sex, smoking status, performance status, TNM stage and chemotherapy regimen. Analysis of the two common polymorphisms based on three genetic models, we found that rs1042522 was not associated with incidence of severe hematologic toxicity. The results showed that rs2279744 was statistically significant risk factor for grade III/ IV hematologic toxicity in additive (adjusted OR = 1.904, 95% CI = 1.149-3.156, P = 0.013) and recessive models (adjusted OR = 2.128, 95% CI = 1.198-3.777, P = 0.010). However, there was no statistically significant association between either the rs1042522 or rs2279744 polymorphism and grade III/IV gastrointestinal toxicity. In addition, the combined effects of rs1042522 and rs2279744 on risk of severe toxicities have not observed in present study. These results suggested that MDM2 rs2279744 might be used as a candidate biomarker for prediction of severe hematologic toxicity in advanced adenocarcinoma patients who had first-line platinum-based chemotherapy.